The ghrelin axis in disease: Potential therapeutic indications

Molecular and Cellular Endocrinology

Volumn 340, Issue 1, 2011, Pages 106-110

  Nass, Ralf ^a   Gaylinn, Bruce D ^a   Thorner, Michael O ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aging; Ghrelin; Ghrelin mimetics; Growth hormone

Indexed keywords

ALENDRONIC ACID; ANAMORELIN; CAPROMORELIN; GHRELIN; IBUTAMOREN; PLACEBO; ULIMORELIN;

AGING; ANOREXIA; CACHEXIA; CANCER CACHEXIA; CARDIAC CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG INDICATION; GLUCOSE HOMEOSTASIS; HIP FRACTURE; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; HYPERALGESIA; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; STOMACH MOTILITY; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL ASSAY; DISEASE; GHRELIN; HUMANS;

EID: 79958168512     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.02.010     Document Type: Review

References (64)

1. Ashby D.R., Ford H.E., Wynne J.K., et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int. 2009, 76:199-206.
2. Bach M.A., Rockwood K., Zetterberg C., et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J. Am. Geriatr. Soc. 2004, 52(4):516-523.
3. Bednarek M.A., Feighner S.D., Pong S.S., et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 2000, 43(23):4370-4376.
4. Bowers C.Y.J., Chang K., Fong T.T.W. A synthetic pentapeptide which specifically releases GH, in vitro. Proc 59th Meeting of The Endocrine Society 1977, 2332.
5. Cappola A. Effects of ghrelin administration in frail and healthy older women. 91st Annual Meeting of the Endocrine Society 2009, 3-495.
6. Cassoni P., Allia E., Marrocco T., Ghe C., Ghigo E., Muccioli G., Papotti M. Ghrelin and cortistatin in lung cancer: expression of peptides and related receptors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line. J. Endocrinol. Invest. 2006, 29:781-790.
7. Chapman I.M., Pescovitz O.H., Murphy G., et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J. Clin. Endocrinol. Metab. 1997, 82(10):3455-3463.
8. DeBoer M.D., Zhu X., Levasseur P.R., et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008, 149:827-835.
9. DeBoer M.D., Zhu X.X., Levasseur P., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007, 148:3004-3012.
10. Delhanty P.J.D., Sun Y.J., Visser A., et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLOS One 2010, 5(7):e11749.
11. Dixit V.D., Schaffer E.M., Pyle R.S., Collins G.D., Sakthivel S.K., Palaniappan R., Lillard J.W., Taub D.D. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest. 2004, 114(1):57-66.
12. Duxbury M.S., Waseem T., Ito H.M., Robinson K.M., Zinner J.S., Ashley W., Whang E.E. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem. Biophys. Res. Commun. 2003, 309:464-468.
13. Esler W.P., Rudolph J.T., Claus H., et al. Small-molecule ghrelin receptor antagonist improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007, 148:5175-5185.
14. Garcia J.M., Cata J.P., Dougherty P.M., Smith R.G. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008, 149(2):455-460.
15. Garcia J.M., Graham C., Kumor K., Polvino W. A phase II, randomized, placebo-controlled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer-cachexia. J. Clin. Oncol. 2007, S25. (Abstract).
16. Gertner J SUN 11031 (synthetic human ghrelin) improves lean body mass and function in advanced COPD cachexia in a placebo controlled trial. 5th International Congress of the GRS and IGF-I Society 2010.
17. Granata R., Volante M., Settanni F., et al. Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J. Mol. Endocrinol. 2010, 45(1):9-17.
18. Groschl M., Uhr M, Kraus T. Evaluation of the comparability of commercial ghrelin assays. Clin. Chem. 2004, 50(2):457-458.
19. Guerlavais V., Boeglin D., Mousseaux D., et al. New active series of growth hormone secretagogues. J. Med. Chem. 2003, 46(7):1191-1203.
20. Gutierrez J.A.P., Solenberg J.D., Perkins R., et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(17):6320-6325.
21. Hanada T., Toshinai K., Kajimura N., et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem. Biophys. Res. Commun. 2003, 7(301):275-279.
22. Helmling S., Maasch C., Eulberg D., et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(36):13174-13179.
23. Hosada H., Kojima M., Matsuo H., Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 2000, 279(3):909-913.
24. Hotta M., Ohwada R., Katakami H., Shibasaki T., Hizuka N., Takano K. Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa. J. Clin. Endocrinol. Metab. 2004, 89(11):5707-5712.
25. Howard A.D., Feighner S.D., Cully D.F., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273:974-977.
26. Kodama T., Ashitani J., Matsumoto N., Kangawa K., Nakazato N. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm. Pharmacol. Ther. 2008, 21:774-779.
27. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
28. Kojima M., Hosoda H., Matsuo H., Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 2001, 12(3):118-122.
29. Korbonits M., Goldstone A.P., Gueorguiev M., Grossman A.B. Ghrelin-a hormone with multiple functions. Front. Neuroendocrinol. 2004, 25(1):27-68.
30. Lasseter K.C., Shaughnessy L., Cummings D., Pezzullo J.C., Wargin W., Gagnon R., Oliva J., Kosutic G. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J. Clin. Pharmacol. 2008, 48(2):193-202.
31. Levin F., Edholm T., Schmidt P.T., et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J. Clin. Endocrinol. Metab. 2006, 91:3296-3302.
32. Liu J, Prudom C.E., Nass R., et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J. Clin. Endocrinol. Metab. 2008, 93(5):1980-1987.
33. Matsumoto M., Hosoda H., Kitajima Y., et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem. Biophys. Res. Commun. 2001, 287(1):142-146.
34. Murphy M.G., Plunkett L.M., Gertz B.J., He W., Wittreich J., Polvino W.M., Clemmons D.R. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J. Clin. Endocrinol. Metab. 1998, 83(2):320-325.
35. Murphy M.G., Weiss S., McClung M., Schnitzer T., Cerchio K., Connor J., Krupa D., Gertz B.J., MK-AS Group Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 2001, 86(3):1116-1125.
36. Nagaya N., Itoh T., Murakami S., Oya H., Uematsu M., Miyatake K., Kangawa K. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005, 128(3):1187-1193.
37. Nagaya N., Kojima M., Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern. Med. 2006, 45(3):127-134.
38. Nagaya N., Moriya J., Yasumura Y., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004, 110:3674-3679.
39. Nass R., Farhy L.S., Liu J., et al. Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. J. Clin. Endocrinol. Metab. 2008, 93(5):1988-1994.
40. Nass R., Johannsson G., Christiansen J.S., Kopchick J.J., Thorner M.O. The aging population-is there a role for endocrine interventions?. Growth Horm. IGF Res. 2009, 19(2):89-100.
41. Nass R., Liu J., Hellmann P., Coschigano K.T., Gaylinn B., Berryman D.E., Kopchick J.J., Thorner M.O. Chronic changes in peripheral growth hormone levels do not affect ghrelin stomach mRNA expression and serum ghrelin levels in three transgenic mouse models. J. Neuroendocrinol. 2004, 16(8):669-675.
42. Nass R., Liu J., Pezzoli S., Oliveri M., Gaylinn B., Thorner M. 24-h Mean acyl-ghrelin levels are decreased in older adults. 4th International Congress of the GRS and the IGF Society 2008, P51.
43. Nass R., Pezzoli S.S., Oliveri M.C., et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann. Intern. Med. 2008, 149(9):601-611.
44. Nass R.M., Gaylinn B.D., Rogol A.D., Thorner M.O. Ghrelin and growth hormone: story in reverse. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(19):8501-8502.
45. Neary N.M., Small C.J., Wren A.M., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004, 89(6):2832-2836.
46. Prudom C., Liu J., Patrie J., Gaylinn B.D., Foster-Schubert K.E., Cummings D.E., Thorner M.O., Geysen H.M. Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels. J. Clin. Endocrinol. Metab. 2010, 95(5):2351-2358.
47. Rauh M., Groschl M., Rascher W. Simultaneous quantification of ghrelin and desacyl-ghrelin by liquid chromatography-tandem mass spectrometry in plasma serum, and cell supernatants. Clin. Chem. 2007, 53(5):902-910.
48. Rigamonti A.E., Pincelli A.I., Corra B., et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J. Endocrinol. 2002, 175(1):R1-5.
49. Smith R.G. Development of growth hormone secretagogues. Endocr. Rev. 2005, 26(3):346-360.
50. Strasser F., Lutz T.A., Maeder M.T., et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br. J. Cancer 2008, 98(2):300-308.
51. Sun Y., Garcia J.M., Smith R.G. Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology 2007, 148(3):1323-1329.
52. Svensson J., Lonn L., Jansson J.O., et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. 1998, 83(2):362-369.
53. Tack J., Depoortere I., Bisschops R., Delporte C., Coulie B., Meulemans A., Janssens J., Peeters T. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006, 55:327-333.
54. Thorner M.O. Statement by the Growth Hormone Research Society on the GH/IGF-I axis in extending health span. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(10):1039-1044.
55. Tong J., Davis H., Nass R., D'Alessio D., Tschop M.H. Effects of ghrelin administration in humans. Obes. Metab. 2009, 5(2):60-68.
56. Tong J., Prigeon R.L., Davis H.W., Bidlingmaier M., Kahn S.E., Cummings D.E., Tschop M.H., D'Alessio D. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010, 59(9):2145-2151.
57. Toshinai K., Mondal M.S., Shimbara T., Yamaguchi H., Date Y., Kangawa K., Nakazato M. Grelin stimulates growth hormone secretion and food intake in aged rats. Mech. Ageing Dev. 2007, 128:182-186.
58. Tschoep M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407(6806):908-913.
59. van der Lely A.J., Tschop M., Heiman M.L., Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25(3):426-457.
60. Wang W., Andersson M., Iresjoe B.M., Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int. J. Oncol. 2006, 28:1393-1400.
61. White H.K., Petrie C.D., Landschulz W., et al. Effects of an oral growth hormone secretagogue in older adults. J. Clin. Endocrinol. Metab. 2009, 94(4):1198-1206.
62. Yeh A.H., Jeffery P.L., Duncan R.P., Herington A.C., Chopin L.K. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin. Cancer Res. 2005, 11:8295-8303.
63. Zdravkovic M., Sogaard B., Ynddal L., Christiansen T., Agerso H., Thomsen M.S., Falch J.E., Ilondo M.M. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN073, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Horm. IGF Res. 2000, 10:193-198.
64. Zhao T.J., Liang G., Li R.L., et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(16):7467-7472.